DHL Group and Cryoport, Inc. have just announced that they have acquired 100 per cent of CRYOPDP, a supply chain solutions provider for the life sciences sector. CRYOPDP is a leading specialty courier focused on clinical trials, biopharma, and cell and gene therapies.
The companies announced a strategic partnership to strengthen their supply chain service offerings for the global life sciences and healthcare sector.
With its Life Sciences and Healthcare business, the acquisition of CRYOPDP is a major step in DHL’s commitment to enhancing its capabilities in specialised pharma logistics and expanding the breadth of its offering in the growing life science and healthcare sector.
Going forward, DHL Supply Chain will further build the potential of its Pharma Specialised Network solution by leveraging the specialty courier expertise of newly acquired CRYOPDP and the global air capabilities of DHL Express and DHL Global Forwarding.
The partnership will bring together DHL’s global health logistics capabilities with Cryoport’s expertise in providing specialised solutions in a fast-growing life science and healthcare market segment.
“The acquisition of CRYOPDP is a pivotal move for our supply chain business as we aim to expand our Pharma Specialized Network to meet the evolving needs of clinical trials, biopharma and cell & gene therapies, in addition to further increasing our footprint in the conventional pharma and life science healthcare segment,” says Oscar de Bok, CEO of DHL Supply Chain.
“The acquisition of CRYOPDP and the extended partnership with Cryoport Inc. will enable us to deliver integrated end-to-end solutions, enhancing our service capabilities.”
“We are indeed pleased to build on our trusted relationship with the DHL Group. Working together we will bring an enhanced set of supply chain solutions to meet companies’ and patients’ critical supply chain needs,” Jerrell Shelton, CEO of Cryoport, commented.
“This strategic partnership taps into the strong expertise of DHL’s Supply Chain and CRYOPDP, presenting a substantial opportunity for Cryoport to further expand its reach to global growth markets such as Asia Pacific (APAC) and Europe, Middle East and Africa (EMEA).”
The acquisition aligns with DHL Group’s Strategy 2030 which emphasises the importance of temperature-controlled networks, first and last mile speciality courier coverage and integrated solutions.
For Cryoport, the partnership will enable it to better execute business in EMEA and APAC with a stronger focus on its business in these regions.